{"id":35156,"date":"2020-11-17T09:33:21","date_gmt":"2020-11-17T09:33:21","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=35156"},"modified":"2021-10-21T15:56:07","modified_gmt":"2021-10-21T14:56:07","slug":"budhesh-dhamija","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/","title":{"rendered":"Budhesh Dhamija"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n\n\t<h2>Budhesh Dhamija<\/h2>\n<h4>Senior Strategist Clinical Regulatory Affairs at ITM Isotopen Technologien M\u00fcnchen AG<\/h4>\n\t<div class=\"su-expand su-expand-collapsed su-expand-link-style-default\" data-height=\"350\"><div class=\"su-expand-content su-u-trim\" style=\"color:#333333;max-height:350px;overflow:hidden\">\n<p>Budhesh Dhamija is currently working in the Clinical Regulatory Affairs department of ITM Oncologics GmbH in Germany. His main responsibilities include developing and implementing global regulatory strategies for complex theragnostic radiopharmaceutical products, including proactive identification of regulatory risks \/ options and mitigation strategies.<\/p>\n<p>Budhesh has previously worked in CSL Behring GmBH and was responsible for monitoring and assessing the European regulatory environment to anticipate and communicate regulatory trends through an understanding of regulatory guidelines, regulations, and laws that may have an impact on CSLB&#8217;s products and regulatory business processes.<\/p>\n<p>Prior to this, Budhesh was employed in Novo Nordisk, Denmark within Safety Surveillance first and then transitioned to the Regulatory Affairs department. Within Safety Surveillance, his main responsibilities included providing process expertise on PSUR\/DSUR preparations, training and cross-project alignment of aggregate reporting. He has authored several regulatory PSURs, DSURs and clinical RMPs according to the defined development milestones or as required by Health Authorities. Additionally, Budhesh was responsible for surveillance of Novo Nordisk products during post-approval phases based on safety information from worldwide sources and communication of drug safety issues internally and to health authorities as required. Within Regulatory affairs, his main responsibilities included to plan, coordinate and execute the regulatory tasks as required in the projects; including RA submission plans for activities such as variations, line extensions, PSURs, RMPs and renewals.<\/p>\n<p>Budhesh has a Masters of Pharmacy (M Pharm) and a Post Graduate Diploma in Advanced Clinical Research, and possesses more than 14 years&#8217; experience in the pharmaceutical industry for several therapeutic areas. Prior to joining Novo Nordisk in 2013, Budhesh was working in a CRO as a Team Leader for Medical writing.<\/p>\n<\/div><div class=\"su-expand-link su-expand-link-more\" style=\"text-align:left\"><a href=\"javascript:;\" style=\"color:#0088FF;border-color:#0088FF\"><span style=\"border-color:#0088FF\">Show more<\/span><\/a><\/div><div class=\"su-expand-link su-expand-link-less\" style=\"text-align:left\"><a href=\"javascript:;\" style=\"color:#0088FF;border-color:#0088FF\"><span style=\"border-color:#0088FF\">Show less<\/span><\/a><\/div><\/div>\n\t\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/11\/Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile_1.png\" alt=\"Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile_1\" itemprop=\"image\" height=\"1224\" width=\"820\" title=\"Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile_1\" onerror=\"this.style.display='none'\"  sizes=\"auto, (max-width: 768px) 100vw, 100vw\" srcset=\"data:image\/svg+xml;utf8,&lt;svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/&gt;\" data-srcset=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/11\/Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile_1.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/11\/Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile_1-201x300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/11\/Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile_1-686x1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/11\/Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile_1-768x1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/11\/Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile_1-630x940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/11\/Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile_1-420x627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/11\/Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile_1-315x470.png 315w\" \/>\t\t\t\t\t\t\t\n<h3>\n\tTitle: Synergies between Regulatory Affairs and Pharmacovigilance\n\t<\/h3>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/itm-radiopharma.com\/\" target=\"_blank\" rel=\"noopener\">https:\/\/itm-radiopharma.com\/<\/a><\/p>\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.linkedin.com\/in\/budheshdhamija\/\" target=\"_blank\" rel=\"noopener\">Visit Profile<\/a><\/p>\n\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Budhesh Dhamija Senior Strategist Clinical Regulatory Affairs at ITM Isotopen Technologien M\u00fcnchen AG Title: Synergies between Regulatory Affairs and Pharmacovigilance On the Web https:\/\/itm-radiopharma.com\/ On LinkedIn Visit Profile<\/p>\n","protected":false},"author":1,"featured_media":35157,"parent":35001,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-35156","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Budhesh Dhamija &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"Budhesh Dhamija is currently working in Global Regulatory Affairs department of CSL Behring GmbH in Germany since June 2018.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Budhesh Dhamija &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"Budhesh Dhamija is currently working in Global Regulatory Affairs department of CSL Behring GmbH in Germany since June 2018.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-21T14:56:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/11\/Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile.png\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/\",\"name\":\"Budhesh Dhamija &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/11\/Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile.png\",\"datePublished\":\"2020-11-17T09:33:21+00:00\",\"dateModified\":\"2021-10-21T14:56:07+00:00\",\"description\":\"Budhesh Dhamija is currently working in Global Regulatory Affairs department of CSL Behring GmbH in Germany since June 2018.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/11\/Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/11\/Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile.png\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharmacovigilance &#038; Drug Safety 2021 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Budhesh Dhamija\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Budhesh Dhamija &#8226; BioTech Pharma Summit","description":"Budhesh Dhamija is currently working in Global Regulatory Affairs department of CSL Behring GmbH in Germany since June 2018.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/","og_locale":"en_US","og_type":"article","og_title":"Budhesh Dhamija &#8226; BioTech Pharma Summit","og_description":"Budhesh Dhamija is currently working in Global Regulatory Affairs department of CSL Behring GmbH in Germany since June 2018.","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-10-21T14:56:07+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/11\/Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/","name":"Budhesh Dhamija &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/11\/Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile.png","datePublished":"2020-11-17T09:33:21+00:00","dateModified":"2021-10-21T14:56:07+00:00","description":"Budhesh Dhamija is currently working in Global Regulatory Affairs department of CSL Behring GmbH in Germany since June 2018.","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/11\/Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/11\/Budhesh_Dhamija_CSL_Behring_BioTech_Pharma_Summit_2021_Profile.png","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/budhesh-dhamija\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Pharmacovigilance &#038; Drug Safety 2021 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/pharmacovigilance-drug-safety-2021-speakers\/"},{"@type":"ListItem","position":3,"name":"Budhesh Dhamija"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/35156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=35156"}],"version-history":[{"count":6,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/35156\/revisions"}],"predecessor-version":[{"id":36758,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/35156\/revisions\/36758"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/35001"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/35157"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=35156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}